Thrasos Therapeutics Initiates Phase 1 Clinical Trial for THR-184 in Acute Kidney Injury

Published: Sep 13, 2011

MONTREAL--(BUSINESS WIRE)--Thrasos Innovation, Inc. today announced that it has initiated a Phase 1 clinical trial to study the safety and tolerability of THR-184, which the Company is developing for the treatment of Acute Kidney Injury (AKI) post-surgery. THR-184 is a proprietary small peptide that selectively activates key receptors of the bone morphogenetic protein (BMP) family responsible for cell and tissue protection, repair and regeneration.

Back to news